Paloma Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Paloma Partners’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-42,039	Closed	-$163K	–	1613
2020 Q3	$163K	Sell	42,039 -49,782	-54%	-$213K	﹤0.01%	1823
2020 Q2	$437K	Buy	+91,821	New	+$378K	0.01%	1289
2019 Q4	–	Sell	-11,200	Closed	-$32K	–	2124
2019 Q3	$32K	Buy	+11,200	New	+$39.1K	﹤0.01%	1887
2018 Q3	–	Sell	-410,305	Closed	-$6.73M	–	1517
2018 Q2	$6.73M	Buy	+410,305	New	+$7.2M	0.12%	130

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Paloma Partners's AMRX Position: Q4 2020 in Review

Paloma Partners sold out of Amneal Pharmaceuticals (AMRX) in Q4 2020, closing a stake of 42,039 shares — an estimated $163K sold.

Paloma Partners first reported a position in AMRX in Q2 2018 and held it in 4 quarters. The position peaked at $6.73M in Q2 2018. 133 funds tracked by Wall St. Rank hold AMRX as of Q4 2020.

Paloma Partners reported no remaining Amneal Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Paloma Partners sold 42,039 Amneal Pharmaceuticals shares in Q4 2020, an estimated $163K.
Paloma Partners first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 4 quarters.
Paloma Partners's Amneal Pharmaceuticals position peaked at $6.73M in Q2 2018.
133 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.